• Sunday, Jun 26, 2022
  • Last Update : 03:54 pm

Oxford vaccine better suited for Bangladesh

  • Published at 12:38 am November 19th, 2020
AstraZeneca vaccine
File photo: A test tube labelled with the Vaccine is seen in front of AstraZeneca logo in this illustration taken on September 9, 2020 Reuters

Pfizer, Moderna vaccines may be unsuitable for countries like Bangladesh, India

While talking about the suitability of several Covid-19 vaccine candidates in development, eminent vaccine scientist Gagandeep Kang of India said the Oxford vaccine may be better compared to the ones being developed by Pfizer or Moderna, for a country like India.

Even though her comments were made keeping India in mind, the conditions she mentioned are applicable for Bangladesh too.

Kang, in an interview with Karan Thapar for The Wire, said the Pfizer vaccine is doubtful to be a solution for India as the country does not have the cold storage facilities needed to store and transport the vaccine at -70° to -80° C. Here, parallels can be drawn between India and Bangladesh as the latter also lacks necessary cold storage facilities.

Moreover, the vaccine being developed by Pfizer has a limited shelf life — as little as one-two days at times.

Meanwhile, the Moderna vaccine needs to be stored at only -20°C and has a shelf life of about 30 days. But the caveat in this case is the price, said the vaccine specialist.

At $37.50 (around Tk3,200) per dose, it is very expensive for countries like India and Bangladesh.

Kang said it is likely that the Oxford vaccine will be a better fit for India. The Oxford vaccine needs to be stored at -2⁰ to -8⁰ — this temperature can be easily achieved by an ordinary refrigerator. And seeing how similar the temperature of the two countries are, this level of temperature requirement can definitely be suitable for Bangladesh too.


Also read - Pfizer says final results show vaccine 95% effective


AstraZeneca, the British pharmaceutical company which is helping manufacture the Oxford vaccine, has partnered with Serum Institute of India to produce one billion doses of the vaccine in India and middle and low-income countries.

According to Adar Poonawalla, the CEO of Serum Institute of India, the cost of the vaccine would be below $13 (Tk1,100), reports The Indian Express.

Considering the two key factors — necessary storage temperature and price, right now it seems that the Oxford vaccine is better suited for the people of Bangladesh compared to the vaccines being developed by either Pfizer or Moderna.

50
Facebook 50
blogger sharing button blogger
buffer sharing button buffer
diaspora sharing button diaspora
digg sharing button digg
douban sharing button douban
email sharing button email
evernote sharing button evernote
flipboard sharing button flipboard
pocket sharing button getpocket
github sharing button github
gmail sharing button gmail
googlebookmarks sharing button googlebookmarks
hackernews sharing button hackernews
instapaper sharing button instapaper
line sharing button line
linkedin sharing button linkedin
livejournal sharing button livejournal
mailru sharing button mailru
medium sharing button medium
meneame sharing button meneame
messenger sharing button messenger
odnoklassniki sharing button odnoklassniki
pinterest sharing button pinterest
print sharing button print
qzone sharing button qzone
reddit sharing button reddit
refind sharing button refind
renren sharing button renren
skype sharing button skype
snapchat sharing button snapchat
surfingbird sharing button surfingbird
telegram sharing button telegram
tumblr sharing button tumblr
twitter sharing button twitter
vk sharing button vk
wechat sharing button wechat
weibo sharing button weibo
whatsapp sharing button whatsapp
wordpress sharing button wordpress
xing sharing button xing
yahoomail sharing button yahoomail